Nerve Growth Factor Regulates Dopamine D2 Receptor Expression in Prolactinoma Cell Lines via p75NGFR-Mediated Activation of Nuclear Factor-
B
Chiara Fiorentini1,
Nicoletta Guerra1,
Marco Facchetti,
Alessandra Finardi,
Laura Tiberio,
Luisa Schiaffonati,
PierFranco Spano and
Cristina Missale
Division of Pharmacology (C.F., N.G., M.F., A.F., P.S., C.M.) and
Division of General Pathology and Immunology (L.T., L.S.), Department
of Biomedical Sciences and Biotechnology, University of Brescia, 25123
Brescia, Italy
Address all correspondence and requests for reprints to: C. Missale, Division of Pharmacology, Department of Biomedical Sciences and Biotechnology, University of Brescia, Via Valsabbina 19, 25123 Brescia, Italy.
 |
ABSTRACT
|
---|
Two groups of prolactinoma cell lines were identified. One group
(responder) expresses both D2 dopamine receptors and an
autocrine loop mediated by nerve growth factor (NGF) and one group
(nonresponder) lacks both D2 receptors and NGF production.
D2 receptor expression in these cell lines is dependent on
NGF. Indeed, NGF inactivation in responder cells decreases
D2 receptor density, while NGF treatment induces
D2 receptor expression in nonresponders.
Here we show that inactivation of p75NGFR, but not of trkA,
resulted in D2 receptor loss in responder cells and
prevented D2 receptor expression induced by NGF in the
nonresponder. Analysis of nuclear factor-
B (NF-
B) nuclear
accumulation and binding to corresponding DNA consensus sequences
indicated that in NGF-secreting responder cells, but not in
nonresponders, NF-
B is constitutively activated. Moreover, NGF
treatment of nonresponder cells induced both nuclear translocation and
DNA binding activity of NF-
B complexes containing p50,
p65/RelA, and cRel subunits, an effect prevented by
anti-p75NGFR antibodies. Disruption of NF-
B nuclear
translocation by SN50 remarkably impaired D2 receptor
expression in responder cells and prevented D2 gene
expression induced by NGF in nonresponders. These data indicate that in
prolactinoma cells the effect of NGF on D2 receptor
expression is mediated by p75NGFR in a trkA-independent way
and that NGF stimulation of p75NGFR activates NF-
B,
which is required for D2 gene expression. We thus suggest
that NF-
B is a key transcriptional regulator of the D2
gene and that this mechanism may not be confined to pituitary tumors,
but could also extend to other dopaminergic systems.
 |
INTRODUCTION
|
---|
NERVE GROWTH FACTOR (NGF) is the first
described member of a family of neurotrophic factors, known as the
neurotrophins, which are required for differentiation and survival of
specific neuronal populations.
NGF binds to two different receptors, trkA and
p75NGFR (1, 2, 3). TrkA, a 140-kDa
protein with intrinsic tyrosine kinase activity, signals via a
ras-dependent pathway leading to activation of the MAPKs
(4, 5, 6) and also through other enzymes, such as
phosphatidylinositol-3 kinase (6, 7).
p75NGFR is a member of the TNF cytokine receptor
superfamily and activates ceramide production (8, 9, 10),
nuclear factor-
B (NF-
B) (10, 11, 12, 13), and c-Jun
N-terminal kinase (JNK) (11, 13, 14). While the role of
trkA in mediating NGF action on cell survival and differentiation is
well established, the functions of p75NGFR are
still a matter of some debate. p75NGFR has been
proposed to act as a coreceptor for trkA (1, 2, 3), to
modulate trkA signaling (1, 2, 3), or to initiate its
independent transduction pathways. The best characterized
trk-independent activity of p75NGFR is regulation
of neuronal cell death and survival (10, 11, 12, 13, 14, 15, 16). Other
p75NGFR-mediated effects have been proposed in
different neuronal systems, including stimulation of dopamine release
from rat mesencephalic neurons (17), regulation of sensory
neuron function and axon growth (18), and Schwann cell
migration (19, 20).
The action of NGF, which was initially found to be restricted to few
populations of neuronal cells, is now known to extend also to different
neuroendocrine systems such as the thyroid and parathyroid glands
(21), the pancreas (22, 23, 24), the prostate
(25, 26, 27, 28), and the pituitary (29, 30, 31, 32). In the
pituitary, NGF and its receptors have been identified in the anterior
lobe (29, 30, 31, 32), where they play a role in the control of
maturation and proliferation of lactotrope cells (33). In
addition, NGF is emerging as a regulator of proliferation and
differentiation of various tumors of neuroendocrine origin
(34, 35, 36) including pituitary PRL-secreting tumors
(37). These are the most frequently occurring neoplasms in
the human pituitary, often express D2 receptors
for dopamine (38), the physiological inhibitor of PRL
secretion (39), and are currently treated with
D2 receptor agonists. Ten to 15% of patients,
however, due to decreased density (40) or loss
(37) of D2 receptors, are refractory
to this pharmacological therapy and require surgical intervention.
In previous studies we have developed and characterized two
phenotypically different groups of human prolactinoma cell lines. Those
derived from tumors refractory to the pharmacological therapy (here
referred to as "nonresponder") are more transformed, have a high
tumorigenic potential, and lack D2 dopamine
receptors, while those obtained from
bromocriptine-sensitive tumors (here referred to as
"responder") are more differentiated, are not tumorigenic, and
express D2 receptors (37). One of
the characteristics of these cell lines is that their phenotype is
highly dependent on the NGF system. In particular, an autocrine loop
that involves the secretion of NGF and the expression of both trkA and
p75NGFR has been identified in the responder
prolactinomas, but not in nonresponders that do not produce NGF and
express trkA but not p75NGFR (41).
The relevance of this mechanism is such that ablation of NGF production
in responder cells leads to transformation and D2
receptor loss, while administration of NGF to nonresponder cells
promotes their differentiation and induces the expression of both
p75NGFR and D2 receptors
(41). The molecular and cellular mechanisms activated by
NGF in these cell lines, however, remain largely unknown. In
particular, which NGF receptor subtype and which intracellular
signaling pathways are involved is still a matter of investigation.
In this study we used two previously characterized prolactinoma cell
lines, one responder and one nonresponder (37, 41), to
define the role of trkA and p75NGFR in
NGF-mediated regulation of D2 receptor gene
expression and to identify the molecular mechanisms that are involved
in this effect. The results show that p75NGFR
plays a critical role, which is independent of trkA, in triggering and
maintaining D2 receptor gene expression in
prolactinoma cells. NGF stimulation of p75NGFR in
these cells results in the activation and nuclear translocation of
NF-
B transcription factor, an effect that is necessary for the
expression of the D2 receptor gene. These data
point to NF-
B as a key transcriptional regulator of the
D2 gene in neuroendocrine cells.
 |
RESULTS
|
---|
Inactivation of p75NGFR Results in the Loss of
D2 Receptors in Responder Cells
We have shown previously that the expression of the
D2 receptor gene in responder prolactinoma cells
is highly dependent on endogenous NGF (41). To evaluate
the role of trkA and p75NGFR in this effect, each
NGF receptor was individually inactivated, and D2
receptor expression was evaluated by both RT-PCR and radioreceptor
binding. In particular, p75NGFR-mediated NGF
activity was inhibited by using two different
anti-p75NGFR antibodies (42, 43),
and trkA was inactivated by inhibiting its intrinsic tyrosine kinase
activity with either genistein or K-252a (44, 45). Control
experiments were performed to evaluate the efficiency and selectivity
of treatments. TrkA and its Tyr490-phosphorylated form were measured by
Western blot by using an enhanced chemiluminescent system allowing
protein detection in the low femtogram range. As shown in Fig. 1A
(upper panel), the
anti-trkA antibody (Cell Signaling Technology) recognized two major
bands in responder cells, one at 110 and one at 140 kDa, consistent
with the presence of differentially glycosylated forms of trkA
(46). The specificity of these bands was confirmed by
immunoreacting the same membrane with another anti-trkA antibody
(Santa Cruz Biotechnology, Inc., Heidelberg,
Germany; not shown). The expression of trkA in responder cells was not
modified by treatments, as shown by the intensity of the 110- and
140-kDa bands. TrkA tyrosine phosphorylation was evaluated with a
phospho-specific antibody detecting its tyr490 phosphorylated form
(47), which binds Shc (48) and initiates the
Ras-MAPK cascade. In responder cells that produce and secrete NGF
(41), trkA appears to be constitutively Tyr490
phosphorylated (Fig. 1A
, middle panel, lanes 1 and 4). A 4-d
exposure to genistein resulted in a significant decrease of Tyr490 trkA
phosphorylation (lane 2). K-252a, however, was less efficient in
inhibiting trkA phosphorylation (lane 3), and the
anti-p75NGFR antibody did not affect it (lane 5).
These observations were further confirmed by evaluating the degree of
phosphorylation of p44/42 MAPK. The results, reported in Fig. 1B
, show
that both p44 and p42 MAPK were constitutively phosphorylated in
untreated responder cells (upper panel, lane 1). A 4-d
exposure to genistein significantly decreased p44/42 MAPK
phosphorylation (lane 2), while K-252a (lane 3) affected it only
slightly. These observations suggest that in our experimental
conditions, genistein, but not K-252a, effectively blocks trkA
function. This result could be in line with the observation that K-252a
is a partial agonist and exerts either inhibitory or stimulatory
effects, depending on the cell phenotype and the experimental
conditions (49). Thus, in subsequent experiments we used
genistein (1 µg/ml) to efficiently block trkA function. The
expression of p75NGFR in responder cells exposed
to the different chemicals was measured by both RT-PCR and Western
blot. Neither p75NGFR mRNA (Fig. 1C
, lane 3), nor
the p75NGFR protein (Fig. 1D
, lane 3) was
modified by a 5-d treatment with the anti-p75NGFR
antibody. This antibody, however, completely inhibited
p75NGFR signaling (see Figs. 5
, 6
, and 7A
),
suggesting that it efficiently blocks
p75NGFR-mediated effects. Exposure of responder
cells to genistein resulted in a slight decrease of
p75NGFR mRNA expression (Fig. 1C
, lane 2).
Genistein, however, did not affect either the levels of the
p75NGFR protein (Fig. 1D
, lane 2) or its
transductional capability evaluated by measuring NF-
B DNA binding
activity (see Fig. 7A
), suggesting that in our experimental conditions
this compound does not interfere with
p75NGFR-mediated mechanisms.

View larger version (32K):
[in this window]
[in a new window]
|
Figure 1. Effects of Genistein, K-252a, and
Anti-p75NGFR Antibody on trkA and p75NGFR
Expression and Function in Prolactinoma Cells
Responder cells were exposed to genistein (1 µg/ml) and K-252a (100
nM) for 4 d and to anti-p75NGFR monoclonal
antibody MC8211 (50 ng/ml) for 5 d. A, Effects of treatments on
trkA expression and tyrosine phosphorylation. Upper
panel, Cell proteins (30 µg/lane) were analyzed for trkA
content as described in Materials and Methods. Two major
bands of 110 and 140 kDa were identified. Lane 1, Untreated cells; lane
2, genistein treatment; lane 3, K-252a treatment; lane 4,
anti-p75NGFR antibody treatment. Middle
panel, Aliquots of cell protein (30 µg/lane) were
immunoreacted with the anti-phospho-trkA (tyr490) antibody (1:1,000
dilution). Lanes 1 and 4, Untreated cells; lane 2, genistein treatment;
lane 3, K-252a treatment; lane 5, anti-p75NGFR antibody
treatment. Lower panel, ß-Tubulin immunostaining: lane
1, untreated cells; lane 2, genistein treatment; lane 3, K-252a
treatment; lane 4, anti-p75NGFR antibody treatment. B,
Effects of treatments on MAPK phosphorylation. Aliquots of cell
proteins (10 µg/lane) were immunoreacted with anti-phospho-p44/42
MAPK antibody (upper panel) or with anti-p44/42 MAPK
antibody (lower panel). Lane 1, Untreated cells; lane 2,
genistein treatment; lane 3, anti-p75NGFR antibody
treatment. C, Effects of treatments on p75NGFR mRNA levels.
The cDNA prepared from untreated and treated cells was PCR amplified as
described in Materials and Methods. Lane 1, Untreated
cells; lane 2, genistein treatment; lane 3, anti-p75NGFR
antibody treatment. D, Effects of treatments on p75NGFR
protein levels. Cell proteins were immunoreacted with
anti-p75NGFR antibody (upper panel) or with
anti-ß-tubulin antibody (lower panel). Lane 1,
Untreated cells; lane 2, genistein treatment; lane 3,
anti-p75NGFR antibody treatment. All experiments were
repeated three times with superimposable results.
|
|

View larger version (161K):
[in this window]
[in a new window]
|
Figure 5. Distribution of NF- B in Untreated and
NGF-Treated Prolactinoma Cells
Untreated and NGF-treated (100 ng/ml; 4 h) cells were fixed with
methanol at -20 C and processed for p65/RelA immunostaining as
described in Materials and Methods. A, distribution of
p65/RelA immunoreactivity in responder cells. The nucleus (solid
arrowheads) and the cytoplasm (open arrowheads)
appear to be equally stained. B, Distribution of p65/RelA
immunoreactivity in nonresponder cells. The immunostaining appears to
be segregated in the cytoplasm (solid arrowheads) with
virtually no nuclear staining (open arrowheads). C, In
NGF-treated nonresponder cells p65/RelA immunostaining appears to be
more concentrated in the nucleus (solid arrowheads) than
in the cytoplasm (open arrowheads); D, in nonresponder
cells treated with NGF in the presence of MC8211
anti-p75NGFR antibody (50 ng/ml), p65/RelA immunoreactivity
was more concentrated in the cytoplasm (open arrowheads)
than in the nucleus (solid arrowheads).
|
|

View larger version (26K):
[in this window]
[in a new window]
|
Figure 6. Western Blot Analysis of p65/RelA in Nuclear and
Cytoplasmic Proteins from Nonresponder Cells
Nuclear (Nucl) and cytoplasmic (Cyt) proteins were immunoblotted with
the anti-p65/RelA antibody as described in Materials and
Methods. The results of a representative experiment are
shown.
|
|

View larger version (51K):
[in this window]
[in a new window]
|
Figure 7. NF- B DNA Binding Activity in Untreated and
NGF-Treated Prolactinoma Cells
A, Nuclear proteins were isolated from untreated responder and
nonresponder cells, from nonresponder cells treated with 100 ng/ml NGF
for 4 h, and from responder cells treated with either genistein (1
µg/ml) for 4 d or anti-p75NGFR antibody (50 ng/ml)
for 5 d. EMSA was performed with [32P]-labeled
NF- B oligonucleotide as a probe. Lanes 1, 4, and 6, Responder cells;
lane 2, nonresponder cells; lane 3, NGF-treated nonresponder cells;
lane 5, genistein-treated responder cells; lane 7, anti
p75NGFR antibody-treated responder cells. B, Dose-response
curve of NGF-induced NF- B DNA binding activity in nonresponder
cells. Cells were exposed to 10100 ng/ml NGF for 4 h, and the
nuclear proteins were isolated and processed for EMSA analysis. Lane 1,
10 ng/ml NGF; lane 2, 50 ng/ml NGF; lane 3, 100 ng/ml NGF; lane 4,
untreated cells. C, Time course of NGF-induced NF- B DNA binding
activity in nonresponder cells. Cells were exposed to 100 ng/ml NGF for
224 h, and the nuclear proteins were isolated and processed for EMSA
analysis. Lane 1, Untreated cells; lane 2, 2 h NGF treatment; lane
3, 4 h NGF treatment; lane 4, 8 h NGF treatment; lane 5,
24 h NGF treatment. The positions of immunoreactive DNA-protein
complexes (solid arrowheads) and of the uncomplexed DNA
(open arrowheads) are shown. D, The molecular
composition of the DNA/protein complex was determined by incubating
nuclear extracts in the presence of antibodies raised against p50 (lane
2), p65/RelA (lane 3), and c-Rel (lane 4) subunits. The specificity of
the antibodies was determined by performing the supershift with
preimmune serum. The positions of the immunoreactive complexes
(solid arrowhead) and the supershifted bands
(open arrowhead) are indicated. The film was overexposed
to detect the supershifted bands.
|
|
The results obtained by RT-PCR analysis of D2
mRNA expression are reported in Fig. 2
.
Amplification of cDNA with D2-specific primers
located within the fourth transmembrane domain and the third
intracellular loop, downstream of the alternatively spliced domain,
revealed that only the D2S mRNA isoform is
present in responder cells, as shown by a single 334-bp band generated
by the PCR reaction (Fig. 2A
, lane 1). This finding was supported by
the observation that the cloned hD2S, used as a
control template, generated a single PCR product of 334 bp (Fig. 2A
, lane 5) and that the direct PCR amplification of the RNA,
i.e. omitting the RT reaction, did not produce any band (not
shown). Exposure of responder cells to
anti-p75NGFR antibodies (Fig. 2A
, lanes 2, 3, and
4) for 5 d, but not to preimmune serum (not shown), resulted in a
dramatic decrease of the D2S mRNA. By contrast, 1
µg/ml genistein (Fig. 2B
, lane 2) given for 4 d did not affect
D2S mRNA expression. Amplification with ß-
actin primers was performed as a control of the amount of cDNA in
each sample (Fig. 2
, A and B). Similar results were obtained in binding
studies with [3H]spiperone. As shown in Fig. 2C
, exposure of cell cultures to MC8211 antibody (50 ng/ml) for 28 d
resulted in a significant decrease of specific D2
binding sites. This effect was evident after a 2-d treatment and was
maximal after 8 d, when specific
[3H]spiperone binding was about 90% decreased.
In line with the results obtained by RT-PCR, both 2- and 4-d exposure
of responder cells to 1 µg/ml genistein did not modify
[3H]spiperone binding. Thus, inhibition of
endogenous NGF-mediated p75NGFR stimulation, but
not trkA inactivation, resulted in D2 receptor
loss in responder cells, suggesting a crucial role for
p75NGFR in regulating D2
receptor gene transcription in this cell line.

View larger version (17K):
[in this window]
[in a new window]
|
Figure 2. The Expression of D2 Receptors in
Responder Prolactinoma Cells Is Selectively Inhibited by Inactivation
of p75NGFR
A, Responder cells were exposed to either MC8211 (50 and 100 ng/ml) or
AB1554 (1:100 dilution) antibody for 5 d, and their cDNA was
amplified by PCR (28 cycles) with D2-specific primers as
described in Materials and Methods. The amount of cDNA
in each sample was determined by PCR amplification with
ß-actin-specific primers (25 cycles). The results of a representative
experiment are shown. Lane 1, Untreated cells; lane 2, MC8211 antibody
treatment (50 ng/ml); lane 3, MC8211 antibody treatment (100 ng/ml);
lane 4, AB1554 antibody treatment; lane 5, hD2S. B,
Responder cells were treated with genistein (1 µg/ml) for 4 d
and processed as in panel A. The results of a representative experiment
are shown. Lane 1, Untreated cells; lane 2, genistein treatment. The
experiments were repeated three times with superimposable results. C,
Cells were exposed to the MC8211 antibody (50 ng/ml) for 28 d or to 1
µg/ml genistein for 24 d, and D2 receptor expression
was evaluated by [3H]spiperone binding as described in
Materials and Methods. Bars represent the means ±
SEM of three independent experiments run in triplicate. **,
P < 0.005 vs. untreated cells; *,
P < 0.001 vs. untreated cells by
t test.
|
|
The Expression of D2 Receptors Induced by NGF in
Nonresponder Cells Is Dependent on p75NGFR
Our data have shown that exposure of nonresponder cells to
exogenous NGF resulted in two temporally distinct events: the
expression of p75NGFR, occurring after 224 h of
treatment (Fig. 3A
and Ref.
41) and the expression of D2
receptors that was detectable by radioreceptor binding after a 2-d
treatment and was maximal after a 5-d treatment (37).
Nonresponder cells were exposed to 100 ng/ml NGF in the absence or in
the presence of anti-p75NGFR antibodies for 5
consecutive days, and D2 receptors were measured
in the different experimental groups. As reported in Fig. 3B
, D2 mRNA was virtually absent in untreated
nonresponder cells (lane 1). Exposure of this cell line to NGF resulted
in a remarkable and selective induction of the
D2S isoform mRNA (lane 2), an effect that was
prevented by anti-p75NGFR antibodies (lanes 3 and
4). The results obtained in binding studies with
[3H]spiperone are reported in Fig. 3C
. While
specific [3H]spiperone binding was undetectable
in untreated cells, exposure to NGF (100 ng/ml; 5 d) resulted in
the appearance of measurable levels of specific
D2 receptor binding. This effect was abolished
when cells were cultured with NGF in the presence of MC8211
anti-p75NGFR antibody (50 ng/ml). Thus, the newly
expressed p75NGFR receptor appears to be
necessary for the stimulatory effect of NGF on D2
receptor expression in nonresponder cells.

View larger version (24K):
[in this window]
[in a new window]
|
Figure 3. Inactivation of p75NGFR Prevents
D2 mRNA Expression Induced by NGF in Nonresponder Cells
A, RT-PCR analysis of p75NGFR expression in nonresponder
cells exposed to NGF for different times. B, RT-PCR analysis of
D2 receptor mRNA expression in non responder cells. Cells
were exposed to 100 ng/ml NGF in the absence or in the presence of
either MC8211 (50 ng/ml) or AB1554 (1:100 dilution)
anti-p75NGFR antibody for 5 consecutive days. Their cDNA
was PCR amplified with either D2 specific primers (35
cycles) or ß-actin primers (25 cycles) as described in
Materials and Methods. The results of a representative
experiment are shown. Lane 1, Untreated cells; lane 2, NGF treatment;
lane 3, NGF and MC8211 antibody treatment; lane 4, NGF and AB1554
antibody treatment. The experiments were repeated three times with
similar results. C, [3H]spiperone binding in nonresponder
cell membranes. Cells were exposed to NGF (100 ng/ml) in the absence or
in the presence of MC8211 antibody (50 ng/ml), and
[3H]spiperone binding was performed as described in
Materials and Methods. Bars represent the
means ± SEM of three independent experiments run in
triplicate. *, P < 0.001 vs.
untreated cells. Note that in untreated cells and in cells exposed to
NGF in the presence of the MC8211 antibody the specific
[3H]spiperone binding was undetectable.
|
|
To further prove that p75NGFR is the NGF receptor
that triggers D2 receptor expression, a fragment
spanning the 5'-flanking region of the human D2
gene (50) was inserted into a luciferase reporter vector
(pGL3-D2) and transiently transfected into COS-7
cells together with an expression vector containing the coding
sequence of p75NGFR receptor. The transfected
cells were exposed to 100 ng/ml NGF for 4 h. As shown in Fig. 4
, NGF did not modify luciferase activity
in cells expressing the D2 promoter construct but
not p75NGFR. However, NGF administration to cells
coexpressing p75NGFR significantly stimulated
D2 promoter-driven luciferase activity. Thus, the
stimulation of p75NGFR in a host cell system
triggers D2 promoter activation, strongly
supporting the view that D2 receptor expression
in prolactinoma cells is dependent on
p75NGFR.

View larger version (16K):
[in this window]
[in a new window]
|
Figure 4. NGF Induces the Transcriptional Activation of the
D2 Promoter-Driven Luciferase Gene in COS-7 Cells
Expressing p75NGFR
COS-7 cells were cotransfected either with the reporter vector
pGL3-D2 alone or in combination with the expression vector
pcDNA-p75NGFR as described in Materials and
Methods. Transfection efficiency in each sample was monitored
by cotransfection with the Renilla luciferase expression
vector. Forty eight hours after transfection cells were cultured in the
absence or in the presence of 100 ng/ml NGF for 4 h, lysed, and
assayed for both firefly and Renilla luciferase
activities. The firefly luciferase activity in each sample was
normalized to Renilla luciferase activity. Open
bars, Untreated cells; solid bars, NGF-treated
cells. Each bar represents the mean ±
SEM of three independent experiments. *,
P < 0.001 vs. untreated cells by
t test.
|
|
NGF Selectively Activates NF-
B in Prolactinoma Cells
One signaling mechanism transduced by
p75NGFR is the activation of NF-
B
(11). This family of transcription factors is composed of
several members that form hetero- and homodimers that are able to
trigger signaling from cell membrane to the nucleus (50, 51).
Since responder and nonresponder cells differ for the production of
NGF, we evaluated both the distribution and the activity of NF-
B in
these cell lines. The cellular localization of p65/RelA was
investigated by immunostaining with a specific monoclonal antibody. As
shown in Fig. 5
, in responder cells
p65/RelA immunostaining appeared to be homogeneously distributed within
the nucleus (Fig. 5A
, solid arrowheads) and the cytoplasm
(Fig. 5A
, open arrowhead). By contrast, in nonresponder
cells p65/RelA immunoreactivity appeared to be preferentially localized
in the cytoplasm (Fig. 5B
, solid arrowheads), with only a
faint nuclear staining (Fig. 5B
, open arrowhead), suggesting
that in responder, but not in nonresponder, cells NF-
B may be
constitutively activated. As reported in Fig. 5C
, exposure of
nonresponder cells to 100 ng/ml NGF resulted in the nuclear
translocation of p65/RelA (solid arrowheads). This
translocation was detectable after a 2-h incubation with NGF, was
maximal after 4 h, and was blocked by the
anti-p75NGFR antibody (Fig. 5D
), indicating that
p75NGFR is necessary for NF-
B activation.
Similar results were obtained in Western blot experiments on isolated
nuclear and cytoplasmic proteins. In untreated cells, p65/RelA
immunoreactivity was more concentrated in the cytosolic than in the
nuclear fraction (Fig. 6
, lanes 1 and 2),
while in NGF-treated cells the nuclear fraction appeared to be highly
enriched in p65/RelA (lanes 3 and 4). p65/RelA nuclear translocation
was prevented by the anti-p75NGFR antibody (lanes
5 and 6).
To demonstrate that NGF-activated NF-
B was able to bind to DNA,
nuclear protein extracts were tested in EMSA using a double-stranded
[32P]-labeled oligonucleotide containing the
characterized NF-
B consensus sequence from the mouse Ig
-gene
(52). As shown in Fig. 7A
, EMSA revealed high DNA binding activity in responder cells (lanes 1, 4,
and 6) and a very low DNA binding activity in nonresponder cells (lane
2). The constitutive NF-
B binding activity detectable in responder
cells was abolished by the anti-p75NGFR antibody
(lane 7), but not by genistein (lane 5), suggesting that it was
entirely due to the interaction of secreted NGF with
p75NGFR. Exposure of nonresponder cells to 100
ng/ml NGF for 4 h resulted in a remarkable up-regulation of the
NF-
B DNA binding activity (lane 3). As shown in Fig. 7B
, this effect
was dose-dependent over the range of 10100 ng/ml. Increasing NGF
concentrations over 100 ng/ml did not result in a further increase of
NF-
B DNA binding activity (not shown). The time dependence of the
effect of NGF is reported in Fig. 7C
. NGF induced up-regulation
of NF-
B activity was detectable after a 2-h treatment (lane 2)
and was maximal within 4 h (lane 3). After 8 h of
stimulation, NF-
B binding activity was still above control (lane 4)
and after a 24-h NGF treatment it was similar to untreated cells (lane
5). To identify the NF-
B subunits activated by NGF in prolactinoma
cells, antibodies specific for various NF-
B peptides were
tested for their ability to either interfere with DNA binding or
supershift DNA-bound activity. Nuclear extracts from NGF-treated
nonresponder were incubated with the
[32P]-labeled NF-
B probe in the absence or
in the presence of antibodies to p50, p65/RelA, and c-Rel subunits. As
shown in Fig. 7D
, all the antibodies interfered with the interaction of
the NF-
B probe with nuclear proteins. In particular, the anti-p50
(lane 2) and anti-c-Rel (lane 4) antibodies inhibited the protein-DNA
binding, while the anti-p65/RelA antibody (lane 3) supershifted the
DNA-protein band, thus suggesting that all three protein subunits are
present in the complexes activated by NGF. By contrast, a preimmune
serum did not significantly modify the DNA-protein binding.
NGF-Inducible NF-
B Is Required for the Expression of the
D2 Receptor Gene
The data reported so far suggest that in human prolactinomas,
p75NGFR is required for NGF-mediated expression
of D2 receptors and that
p75NGFR activation results in the stimulation
of NF-
B binding activity. To investigate whether NF-
B is the
cellular signal required for D2 receptor gene
transcription, we used SN50, a cell-permeable peptide containing the
nuclear localization sequence from the p50 subunit of NF-
B,
which is known to inhibit translocation of the NF-
B active complex
into the nucleus (53). Since in responder cells, which
spontaneously express D2 receptors, NF-
B
appears to be constitutively activated, we evaluated whether
SN50-induced inhibition of NF-
B nuclear translocation may affect
D2 receptor expression. Responder cells were thus
exposed to either 100 µg/ml SN50 or 100 µg/ml SN50M, an inactive
control peptide mutated within the nuclear localization sequence motif,
for 26 d. As a control of the efficiency of these treatments, NF-
B
cell localization was evaluated by p65/RelA immunostaining. The results
showed that SN50, but not SN50M, completely inhibited p65/RelA nuclear
translocation (data not shown). Moreover, as shown in Fig. 8A
, exposure of responder cells to SN50
for 2 and 6 d resulted in a dramatic down-regulation of
D2S mRNA expression (lanes 2 and 3). By contrast,
the levels of D2S mRNA were unchanged in cells
treated with SN50M for 6 d (lane 4). Similarly, as reported in
Fig. 8B
, the stimulatory effect of NGF (100 ng/ml; 5 d) on
D2S mRNA expression in nonresponder cells (lane
2) was lost when NGF treatment was performed in the presence of 100
µg/ml SN50 (lane 3), but not SN50M (lane 4).

View larger version (18K):
[in this window]
[in a new window]
|
Figure 8. The NF- B-Inhibitory Peptide SN50 Abolishes
D2 Receptor Expression in Prolactinoma Cells
A, Responder cells were treated with 100 µg/ml SN50 or 100 µg/ml
SN50M for 2 and 6 d, and the cDNA obtained from untreated and
treated cells was PCR amplified with D2-specific primers
(28 cycles) as described in Materials and Methods. Lane
1, Untreated cells; lane 2, 2-d SN50 treatment; lane 3, 6-d SN50
treatment; lane 4, 6-d SN50M treatment. B, Nonresponder cells were
exposed to 100 ng/ml NGF in the absence or in the presence of either
100 µg/ml SN50 or 100 µg/ml SN50M for 5 d. The cDNA obtained
from untreated and treated cells was subjected to PCR amplification
with D2-specific primers (35 cycles). Lane 1, Untreated
cells; lane 2, NGF-treated cells; lane 3, NGF/SN50-treated cells; lane
4, NGF/SN50M-treated cells. The amount of cDNA in each sample was
determined by PCR amplification with ß-actin specific primers (25
cycles). The results of representative experiments are shown.
|
|
To definitely prove that NF-
B regulates D2
receptor expression, the luciferase reporter vector containing the
D2 promoter was transiently transfected into
COS-7 cells together with expression vectors containing the
B-related species p50 and c-Rel. As shown in Fig. 9
, expression of p50 by itself or in
combination with c-Rel led to a significant increase of
D2 promoter-driven luciferase activity, while the
expression of c-Rel alone was devoid of effects on the reporter
gene transcription. These data indicate that NF-
B is a necessary and
sufficient signal to induce D2 gene
expression.

View larger version (16K):
[in this window]
[in a new window]
|
Figure 9. Transcriptional Activation by NF- B Subunits of
the D2 Receptor Promoter
COS-7 cells were cotransfected with the reporter vector
pGL3-D2 and either the pSG-p50, pSG-c-Rel, or the
combination pSG-p50/pSG-c-Rel as described in Materials and
Methods. Transfection efficiency in each sample was monitored
by cotransfection with the Renilla luciferase expression
vector. Forty-eight hours after transfection cells were lysed and
assayed for both firefly and Renilla luciferase
activities. The firefly luciferase activity in each sample was
normalized to Renilla luciferase activity. Each
bar represents the mean ± SEM of three
independent experiments. *, P < 0.001
vs. pGL3-D2, t test.
|
|
 |
DISCUSSION
|
---|
The p75NGFR NGF receptor, although long
believed to primarily act as a coreceptor for trkA (1, 2, 3),
is now emerging as being also capable of autonomous functions. On this
line some independent activities of
p75NGFR have been proposed in the nervous system
(10, 15, 16, 17, 18, 19, 20). However, although ceramide
(8, 9, 10), NF-
B (10, 11, 12, 13), and JNK (11, 13, 14) have been identified as potential
p75NGFR-dependent signaling effectors, only in a
few cases has their direct involvement in specific
p75NGFR-mediated neuronal functions been
elucidated (9, 10, 12, 13, 16, 55). The role of trkA and
p75NGFR in the neuroendocrine effects of NGF has
been only partially investigated. In particular, some studies suggested
the involvement of trkA in the regulation of pancreas morphogenesis
(22, 23, 24), one study correlated the activation of trkA with
the control of prostate cancer cell line proliferation
(56), and fragmentary data indirectly correlated the loss
of p75NGFR with the progression of prostate
cancer (27, 28) and its expression with the
antiproliferative effects of NGF on thyroid tumor cells
(34). On the other hand, the signaling mechanisms
activated by each NGF receptor subtype in neuroendocrine tissues are
still elusive.
In previous studies we have shown that the expression of
D2 receptors for dopamine in pituitary
PRL-secreting tumor cell lines is correlated with their degree of
transformation and is highly dependent on an endogenous autocrine loop
mediated by NGF (37, 41). We now report that, in these
prolactinoma cell lines, the expression of the D2
gene is regulated by the p75NGFR NGF receptor in
a trkA-independent way. Moreover, we identified the NF-
B
transcription factor as the NGF-activated,
p75NGFR-dependent intracellular signaling
molecule that is required for D2 receptor gene
transcription.
The demonstration that p75NGFR is indeed the
receptor that mediates the effect of NGF on D2
gene expression came from the results obtained with the
anti-p75NGFR antibodies and in transfection
experiments. In the more differentiated responder cells inhibition of
endogenous NGF interaction with p75NGFR resulted
in D2 receptor loss. Similarly, when the
p75NGFR receptor was inactivated during NGF
administration to the more transformed nonresponder cells, the
stimulatory effect of NGF on D2 receptor
expression was lost. These data thus suggest that, when
p75NGFR signaling is negated, the selective
activation of trkA-mediated pathways is not sufficient, per
se, to sustain D2 receptor gene
transcription. Moreover, the data obtained with the tyrosine kinase
inhibitor genistein argue against the possibility of a functional
interaction between trkA and p75NGFR in
NGF-mediated regulation of D2 receptor
expression. Disruption of trkA signaling did not modify, in fact, the
levels of D2S mRNA and protein in responder
cells, suggesting that D2 receptor expression is
under the exclusive control of p75NGFR and its
signaling effectors. This conclusion is further supported by the
finding that NGF triggers D2 promoter-directed
luciferase transcription in COS-7 cells expressing
p75NGFR, but not in those lacking it. In line
with this is the observation that in prolactinoma cells there is a
close correlation between p75NGFR and
D2, but not trkA and D2
receptor expression levels (41). It should be noted,
however, that genistein slightly down-regulates
p75NGFR mRNA in responder cells. Although this
decrease was not accompanied by a correspondent decrease of
p75NGFR protein and transductional efficiency, it
could be inferred that a longer inhibition of trkA could actually
down-regulate the p75NGFR receptor. On this
line we had previously shown that p75NGFR
expression in prolactinomas is highly dependent on NGF
(41) and that a deprivation of secreted NGF for at least
6 d was necessary to induce p75NGFR protein
loss in responder cells (41). These observations suggest
that trkA could indirectly contribute to the effects of NGF on
D2 gene transcription by inducing and maintaining
the expression of p75NGFR. Moreover, it cannot be
excluded that, as in other cell models, in prolactinoma cells
p75NGFR and trkA may also directly interact to
mediate other specific effects of NGF such as inhibition of cell
proliferation and abrogation of tumorigenicity (37).
The D2 dopamine receptor is known to exist as two
different isoforms, called D2S and
D2L, which are generated by alternative splicing
from the same gene and which are mostly colocalized in the same tissues
(39). In particular, in the anterior pituitary,
D2S and D2L receptor
isoforms are expressed in lactotrope cells, where the longer form is
predominant (39). PCR amplification of
D2 cDNA in responder prolactinomas revealed that,
unlike their physiological counterpart, these cells express only the
D2S receptor isoform. Furthermore, exposure of
nonresponder prolactinomas to NGF resulted in the selective expression
of D2S mRNA. Different mechanisms may be invoked
to explain this finding. It could be possible that genetic alterations
occurring during lactotrope cell transformation led to the loss of the
D2L isoform. On the other hand, it is also
possible that NGF affects the splicing mechanisms leading to the
selective expression of the D2S receptor isoform.
In line with this view, subpopulations of lactotropes have been
identified that may express different
D2S/D2L mRNA ratios in
response to different stimuli (57), and activated sex
steroid receptors have been reported to modulate the alternative
splicing of the D2 receptor mRNA in the MMQ
pituitary cell line (58).
How does p75NGFR induce the expression of
D2 receptors in prolactinoma cells? Our analysis
of the signaling molecules activated by NGF strongly pointed to NF-
B
transcription factors as the most plausible candidates. The NF-
B
family is composed of several distinct DNA binding subunits that can
hetero- and homodimerize, thereby forming complexes with distinct cell
type distribution, DNA sequence specificity, and transcriptional
activity (51, 52). In its inactive state, NF-
B is
sequestered into the cytoplasm by binding to I
B proteins (51, 52). Responder and nonresponder prolactinomas showed a different
pattern of NF-
B activation, likely due to the presence or the
absence of secreted NGF in the culture media. In particular, in the
NGF-secreting responder cells, but not in the nonresponder cell lines,
NF-
B appears to be constitutively activated. Furthermore, exposure
of nonresponder cells to NGF promoted the nuclear translocation and
induced the DNA binding activity of NF-
B complexes containing p50,
p65/RelA, and c-Rel subunits in a dose- and time-dependent way, an
effect mediated by p75NGFR with apparently no
contribution of trkA. When p75NGFR activation was
blocked by a specific antibody, the selective NGF stimulation of trkA
failed, in fact, to promote NF-
B translocation. This finding is in
line with the observation that, in cultured oligodendrocytes, trkA does
not modify p75NGFR-mediated induction of NF-
B,
while suppressing p75NGFR-induced JNK activation
(13). However, it is worth noting that both
p75NGFR and trkA have been recently reported to
activate NF-
B in PC12 cells (12). Our data, showing
that trkA inactivation by genistein did not modify the constitutive
NF-
B activity in responder cells, while the
p75NGFR antibody abolished it, suggest that in
this cell line NF-
B activation is entirely dependent on
p75NGFR. Thus, the evidence is increasing that
the cell phenotype strongly influences the type of signaling and of
interaction between p75NGFR and trkA.
As in other cell systems, activation of NF-
B complexes in
prolactinoma cells was inhibited by SN50, a cell-permeable peptide that
specifically inhibits nuclear translocation of p50-containing NF-
B
complexes (54). By using SN50, we were able to demonstrate
that NF-
B activation is a critical step in the regulation of
D2 receptor gene transcription. SN50, in fact,
not only prevented NF-
B activation, but also abolished
D2 receptor expression in both responder and
NGF-treated nonresponder prolactinoma cells. This conclusion is
strongly supported by the results of cotransfection experiments showing
that NF-
B complexes including the p50 homodimer and the p50/c-Rel
heterodimer increase the transcriptional activity of a
D2 promoter-driven reporter gene. Interestingly,
differences in the transcriptional activity were observed with the two
different p50-containing complexes. Although the reason for these
differences has not been addressed directly, this observation is in
agreement with previous data by other groups (59, 60).
Thus, p75NGFR-mediated stimulation of NF-
B
activity provides a molecular mechanism underlying the stimulatory
action of NGF on D2 receptor gene expression.
Analysis of the D2 receptor promoter revealed
that it has the characteristics of a housekeeping gene (61, 62), suggesting that the specificity in the expression pattern
of this receptor must be dictated spatially and temporally by
cell-specific transcription factors. On this line various regulatory
sequences, including Sp1, AP-1, AP-2, and RA-response element,
have been identified in the rat D2 promoter
(61, 62, 63, 64). However, only for retinoids has a role in the
physiological regulation of D2 receptor
expression been clearly demonstrated (65, 66). Our present
data first point to NF-
B as another key transcriptional regulator of
the D2 gene in neuroendocrine cells. Our
observation that the human D2 promoter contains
at least one consensus sequence able to specifically bind NF-
B
complexes (Guerra, N., C. Fiorentini, and C. Missale,
manuscript in preparation) supports this view and suggests that
the role of NF-
B in the regulation of D2
receptor gene transcription may not be confined to pituitary tumors,
but could extend also to other dopaminergic systems.
The regulation of D2 receptor gene transcription
appears to be a key element in the function of the dopaminergic
systems. Deletion of the D2 receptor gene in
knockout animals results in both nervous and pituitary dysfunctions
(67, 68, 69) and ablation of specific retinoid receptors, by
impairing the control imposed by retinoids on D2
gene transcription, leads to specific neurological symptoms in the null
animals (65).
Our data raise the possibility that dysregulations in the expression or
function of NF-
B transcription factors, resulting in an aberrant
control of D2 receptor gene expression, may lead
to specific neuroendocrine disorders.
 |
MATERIALS AND METHODS
|
---|
Prolactinoma Cell Cultures and Treatments
Two prolactinoma cell lines (one nonresponder and one
responder), previously developed and characterized in our laboratory
(37, 41), were used in this study. Cells were grown in
Hams F10 medium supplemented with 2.5% FCS, 15% horse serum, 4
mM glutamine, and 100 U of penicillin-streptomycin
(F10+).
Cells were cultured under the following conditions: responder cells
were grown in F10+ containing 1) either 1 µg/ml genistein (RBI,
Natick, MA) or 100 nM K-252a (BIOMOL Research Laboratories, Inc., Hamburg, Germany) for 24 d without further
medium changes; 2) either the antihuman p75NGFR
monoclonal antibody MC8211 (50100 ng/ml; Roche Molecular Biochemicals, Milano, Italy) or a polyclonal
anti-p75NGFR antibody (1:100 dilution, AB1554
Chemicon International, Roma, Italy) for 28 d with the antibodies
added to the culture medium every day; 3) either SN50 or SN50M (100
µg/ml; BIOMOL Research Laboratories, Inc.) for 26 d
with the peptides added to the cultures every day. Nonresponder cells
were grown in F10+ containing: 1) 100 ng/ml NGF (2.5S, mouse, Alomone
Labs, Jerusalem, Israel) in the absence or in the presence of the
anti-p75NGFR antibodies for either 224 h or
5 d. NGF was added once at the beginning of treatment, and the
antibodies were added to the cultures every day; 2) 100 ng/ml NGF in
the absence or in the presence of either SN50 or SN50M (100 µg/ml)
for 5 d with NGF added once at the beginning of treatment and the
peptides added to the cultures every day.
Detection of D2 and p75NGFR Receptors by
RT-PCR
Total RNA was isolated from cells using the SV Total RNA
Isolation System (Promega Corp., Milano, Italy). Four
micrograms of each sample were transcribed into cDNA by using the
murine Moloney leukemia virus reverse transcriptase (Promega Corp.) and oligo(dT)18 (Promega Corp.) as a primer. To amplify the D2
receptor the oligonucleotides 5'-TCCTGCCCACTCCTCTTCGGACTC-3' encoding
human D2 residues SCPLLFGL and
5'-AGAGTCAGCTGGTGGTGGCTGGG-3' encoding human D2
residues PSHHQLTL (MWG Biotech, Firenze, Italy) were used.
Reactions were performed for either 28 or 35 cycles (95 C, 30 sec; 57
C, 30 sec; 72 C, 1 min) within the linear range of amplification.
Omission of the reverse transcription reaction and amplification of
cloned human D2S cDNA
(hD2S) were performed as a control of the PCR
specificity. The p75NGFR receptor was amplified
with 5'-AGCCAACCAGACCGTGTGT-3' and 5'-TTGCAGCTGTTCCACCTCTT-3'
primers encoding human p75NGFR residues GANQTV
and EGEKLH, respectively. Reactions were performed for 28 cycles (95 C,
30 sec; 58 C, 30 sec; 72 C, 1 min) within the linear range of
amplification. Omission of the reverse transcription reaction and
amplification of cloned human p75NGFR cDNA were
performed as a control of the PCR specificity.
Amplification with 5'-TAAAGACCTCTATGCCAACACAGT-3' and
5'-CACGATGGAGGGCCGGACTCATC-3' primers encoding human ß-actin residues
KDLYANTV and DESGPSIV, respectively (95 C, 30 sec; 60 C, 30 sec; 72 C,
1 min; 25 cycles), was performed as a control of the amount of cDNA
used in each sample. The PCR products were analyzed on 1% agarose gels
stained with ethydium bromide.
Detection of D2 Receptors by
[3H]Spiperone Binding
The F10+ medium was replaced with ice-cold 50 mM
Tris-HCl (pH 7.4), and cells were detached from plates and centrifuged
at 800 x g for 10 min. Cells were resuspended in
ice-cold 50 mM Tris-HCl (pH 7.4), homogenized
with an Ultra-Turrax homogenizer (two 15-sec bursts), and centrifuged
at 100,000 x g for 15 min at 4 C. The resulting
pellets were resuspended in ice-cold 50 mM
Tris-HCl containing 120 mM NaCl, 5
mM KCl, 2 mM
CaCl2, 1 mM
MgCl2, 0.1% ascorbic acid, pH 7.4. Aliquots of
the membrane suspension (80100 µg protein/sample) were incubated
with 1 nM [3H]spiperone
(108 Ci/mmol; Amersham International, Milano, Italy) for
10 min at 37 C. The nonspecific binding was defined with 1
µM l-sulpiride (RBI). Incubations were stopped
by rapid filtration under reduced pressure through GF/B filters
(Whatman, Clifton, NJ).
Immunocytochemistry
Cells were plated at low density on
poly-L-lysine-coated glass coverslips, fixed with methanol
at -20 C for 5 min, incubated in PBS containing 0.2% Triton X-100 and
10% normal goat serum (Santa Cruz Biotechnology, Inc.,
Heidelberg, Germany) for 10 min at room temperature to mask nonspecific
absorption sites, and then incubated overnight at 4 C with a monoclonal
antibody to p65/RelA (1:200 dilution in PBS containing 1% normal goat
serum; Roche Molecular Biochemicals, Milano, Italy). Cells
were then incubated with the biotinylated goat antimouse secondary
antibody (1:400 dilution; Santa Cruz Biotechnology, Inc.)
for 1 h at room temperature. After three rinses with PBS, cells
were incubated with the avidin-biotin complex (ABC kit, DAKO Corp. S.p.A., Milano, Italy) for 45 min at room temperature.
Peroxidase staining was obtained by incubation in 0.06%
3,3'-diaminobenzidine and 0.01%
H2O2 in PBS buffer.
SDS-PAGE and Immunoblotting
Cells were detached from plates in PBS containing 100
µM pyrrolidine dithiocarbamate (Sigma-Aldrich Corp., Milano, Italy) to block NF-
B activation during the
harvest procedure and centrifuged at 800 x g for 10
min. The cell pellets were resuspended in ice-cold 40
mM Tris-HCl containing 150
mM NaCl and 10 mM EDTA (pH
7.5), incubated on ice for 10 min, mixed by vortex for 10 sec, and
centrifuged at 12,000 x g for 15 sec at room
temperature. The resulting supernatants containing the cytoplasmic
proteins were stored at -20 C. The pellets were resuspended in 10
mM Tris-HCl (pH 7.5) containing 5
mM EDTA, 1 mM
phenylmethylsulfonylfluoride (PMSF), 10 µg/ml leupeptin, and 10
µg/ml pepstatin, incubated on ice for 20 min, and centrifuged at
18,000 x g for 2 min at 4 C. The resulting
supernatants containing the nuclear proteins were stored at -20 C.
Aliquots of cytoplasmic and nuclear proteins (50 µg protein/lane)
were resolved on 12% SDS-PAGE and transferred onto polyvinylidene
difluoride membranes. After blotting for 1 h at room temperature
in Tris-buffered saline (TBS) containing 0.1% Tween 20 and 5%
nonfat powdered milk (Blotto A), membranes were incubated overnight at
4 C with the monoclonal anti-p65/RelA antibody (1:100 dilution in
Blotto A; Santa Cruz Biotechnology, Inc.). For detection,
an ECL chemiluminescence system (Amersham International,
Milano, Italy) was used with a horseradish peroxidase (HRP)-conjugated
secondary antibody (1:2,000 dilution; Santa Cruz Biotechnology, Inc.).
In another group of experiments, cells were resuspended in a lysis
buffer containing 50 mM Tris-HCl (pH 7.6), 150
mM NaCl, 5 mM EDTA, 0.5% Triton X-100, 0.1%
SDS, 1 mM NaF, 1 mM
Na3VO4, and a complete set
of protease inhibitors (Complete Mini Protease Inhibitors, Roche Molecular Biochemicals), incubated on ice for 20 min, and
centrifuged at 18,000 x g for 2 min at 4 C. The
resulting cell extracts were stored at -20 C. To detect trkA and its
phosphorylated forms, aliquots of cell extracts (30 µg protein/lane)
were resolved on 6% SDS-PAGE, transferred onto nitrocellulose
membranes, and blotted for 1 h at room temperature in Blotto A.
Membranes were then incubated overnight at 4 C with 1) anti-trkA
antibody (1:1,000 dilution in Blotto A; Cell Signaling Technology,
Milano, Italy); 2) anti-phospho-trkA (Tyr490) antibody (1:1,000
dilution in TBS containing 5% BSA and 0.1% Tween 20; Cell Signaling
Technology). For detection, an enhanced chemiluminescent system
allowing visualization of proteins in the low femtogram range
(SuperSignal West; Pierce Chemical Co., Milano, Italy)
with a HRP-conjugated secondary antibody (Pierce Chemical Co.) was used. To detect MAPK, cell extracts (10 µg
protein/lane) were resolved on 10% SDS-PAGE and processed as
previously described. Membranes were incubated overnight at 4 C with
anti-p44/42 MAPK antibody (1:1,000 dilution in TBS containing 5%
BSA and 0.1% Tween 20; Cell Signaling Technology) or with the
anti-phospho-p44/42 MAPK (Thr202/Tyr204) antibody (1:1,000 dilution
in TBS containing 5% BSA and 0.1% Tween 20; Cell Signaling
Technology). To detect p75NGFR, cell extracts (30
µg protein/lane) were resolved on 7.5% SDS-PAGE, transferred onto
polyvinylidene difluoride membranes, blotted for 1 h at room
temperature in Blotto A, and incubated overnight at 4 C with the
anti-p75NGFR antibody (1:1,000 dilution in TBS
containing 3% nonfat powdered milk and 0.1% Tween 20; Promega Corp.). The amount of proteins in each lane was checked by
immunoreaction with ß-tubulin antibody (1:1,500 dilution in TBS
containing 5% nonfat powdered milk and 0.1% Triton X-100;
Neo-Markers, Fremont, CA). For detection, an ECL chemiluminescence
(Amersham International) system with HRP-conjugated
secondary antibodies (1:2,000 dilution; Santa Cruz Biotechnology, Inc.) was used.
Nuclear Extracts and EMSA
Cells were rinsed with ice-cold PBS and harvested by scraping
with ice-cold PBS containing 100 µM pyrrolidine
dithiocarbamate. Cells were pelleted at 4 C (800 x g,
5 min), lysed in 500 µl of ice-cold 10 mM
HEPES, pH 7.9, containing 10 mM KCl, 1.5
mM MgCl2, 0.5
mM dithiothreitol (DTT), 0.5
mM PMSF, and a complete set of protease
inhibitors (Complete Mini Protease Inhibitors, Roche Molecular Biochemicals) and centrifuged at 800 x g at 4 C
for 5 min. The resulting pellet was resuspended in 500 µl of the
lysis buffer described above with the addition of 0.5% NP-40,
homogenized with a Dounce homogenizer, and centrifuged at 2,500 x
g for 5 min at 4 C. The resulting pellet, containing the
nuclei, was resuspended in 30 µl of ice-cold 20
mM HEPES, pH 7.9, containing 420
mM NaCl, 1.5 mM
MgCl2, 0.2 mM EDTA, 25%
glycerol, 0.5 mM DTT, 0.5
mM PMSF, and the complete set of protease
inhibitors, incubated on ice for 20 min, and centrifuged at 14,000
x g for 15 min at 4 C. The supernatant containing the
nuclear proteins was stored at -80 C. Protein concentration was
assessed by Bradford assay according to the manufacturers
instructions (Bio-Rad Laboratories, Inc., Hercules, CA).
DNA binding reactions were initiated by combining 10 µg of nuclear
extracts with 100,000 cpm (0.5 ng) of
-[32P]-labeled oligonucleotide in 25 µl of
10 mM Tris-HCl, pH 7.5, containing 50
mM NaCl, 1 mM DTT, 1
mM EDTA, 0.5 µg poly(dIdC). Reactions were
carried out for 20 min at room temperature, and protein-DNA complexes
were resolved on a nondenaturing 5% polyacrylamide gel in
Tris/borate/EDTA buffer. Gels were dried and subjected to
autoradiography at -80 C by using Kodak Biomax MR films
(Eastman Kodak Co., Rochester, NY). In supershift
experiments, 10 µg of nuclear extracts were incubated for 1 h at
4 C with selected antibodies before addition of the other components of
the reaction mixture. Incubation was continued for an additional 20 min
at room temperature. The following antibodies were used: a monoclonal
anti-p50 antibody (Santa Cruz Biotechnology, Inc.); a
monoclonal anti-p65/RelA antibody (Santa Cruz Biotechnology, Inc.); a monoclonal anti-p65/RelA antibody (Roche Molecular Biochemicals); and a monoclonal anti-cRel antibody
(Santa Cruz Biotechnology, Inc.). Preimmune serum was used
as a control of antibody specificity.
Synthetic DNA Oligonucleotides
The specific NF-
B oligonucleotide
5'-GGATCCTCAACAGAGGGGACTTTCCGAGGCCA-3' and its complementary strand
were used. For gel shift analysis, 200 ng of the sense oligonucleotide
were end labeled with
-[32P]ATP (3,000
Ci/mmol; NEN Life Science Products, Milano, Italy) and T4
polynucleotide kinase (Promega Corp.) for 1 h at 37
C. The labeled oligonucleotide was annealed with its complementary
strand for 3 min at 90 C, 10 min at 65 C, 10 min at 37 C, and 5 min at
room temperature, and the double-stranded oligonucleotide was purified
by denaturing 20% polyacrylamide gel electrophoresis.
Plasmid Construction
A fragment consisting of 284 bp of the 5'-flanking sequence and
20 bp of the first exon of the human D2 gene was
obtained by a two-step PCR with the sense primer
5'-ACTGGCGAGCAGAGCGTGAGGACCC-3' and antisense primer
5'-TGCGCGCGTGAGGCTGCCGGTTCGGC-3' according to Arinami et al.
(70). The KpnI linker was added to sense and
the HindIII linker was added to antisense primer. The
reaction was performed with native Pfu polymerase
(Stratagene, Milano, Italy) at 98 C for 1 min followed by
35 cycles of 98 C for 20 sec and 75 C for 5 min. PCR reaction buffer
was supplemented with 4% formamide. After sequencing, the generated
fragment was cloned into the luciferase reporter plasmid pGL3-basic
(Promega Corp.). The
B/Rel expression plasmids pSG-p50
and pSG-cRel have been described previously (71). The
p75NGFR coding sequence was subcloned into the
BamHI/XhoI restriction sites of the pcDNA3.1
expression vector (Invitrogen, Milano, Italy).
Cell Transfection and Luciferase Activity
COS-7 cells (6080% confluent) were transiently cotransfected
for 3 h with 1) pGL3-D2 (1 µg) and the
empty pSG vector (2 µg); 2) pGL3-D2 (1 µg),
pSG-p50 (1 µg), and pSG (1 µg); 3) pGL3-D2 (1
µg), pSG-p50 (1 µg), and pSG-cRel (1 µg); 4) pGL3-D2 (1 µg),
pSG-cRel (1 µg), and pSG (1 µg); 5) pGL3-D2
(1 µg) and pcDNA-p75NGFR (1 µg), using the
lipofectine (LipofectAMINE Reagent, Invitrogen-Life
Technologies, Milano Italy) technique. Transfection efficiency
throughout the experiments was monitored by cotransfection with a
Renilla luciferase expression vector (50 ng). After
transfection, cells were cultured in the complete medium for 48 h.
Cells cotransfected with pGL3-D2 and
pcDNA-p75NGFR were treated with 100 ng/ml NGF for
4 h. Cells were harvested, lysed, and assayed for luciferase
activities by using the Dual-Luciferase Reporter Assay System
(Promega Corp.) according to the manufacturers
instructions. Firefly luciferase activity in each sample was normalized
to Renilla luciferase activity.
 |
ACKNOWLEDGMENTS
|
---|
We thank Dr. Marc Caron for his gift of the human
D2S cDNA; Dr. Karen L. OMalley, for her gift of
the human D2 promoter; Dr. Mariagrazia Grilli and
Dr. Pierre Jalinot for kindly providing the pSG-p50 and pSG-c-Rel
expression vectors; Dr. Moses V. Chao, for providing the
p75NGFR cDNA; Dr Monica Di Luca and Dr. Francesca
Colciaghi for their help and advice in the Western blot studies; Dr.
Laura Bianchi for her gift of the pGL3 basic and Renilla
vectors; and Dr. Roberto Bresciani for his gift of COS-7 cells and his
help and advice in construct preparation and transfection
experiments.
 |
FOOTNOTES
|
---|
This work was supported by grants from Ministero
dellUniversità e della Ricerca Scientifica e Tecnologica
(9706151106), Consiglio Nazionale delle Ricerche (99.02532.CT04) and
AIRC Associazione Italiana per la Ricerca sul Cancro (to
C.M.).
1 These authors contributed equally to this work. 
Abbreviations: DTT, Dithiothreitol; HRP, horseradish
peroxidase; JNK, c-Jun N-terminal kinase; NF-
B, nuclear factor
B;
NGF, nerve growth factor; PMSF, phenylmethylsulfonylfluoride; TBS,
Tris-buffered saline.
Received for publication December 6, 2000.
Accepted for publication October 10, 2001.
 |
REFERENCES
|
---|
-
Bothwell M 1995 Functional interactions of neurotrophins
and neurotrophin receptors. Annu Rev Neurosci 18:223253[CrossRef][Medline]
-
Lewin GR, Barde YA 1996 Physiology of the neurotrophins. Annu
Rev Neurosci 19:289317[CrossRef][Medline]
-
Chao MV, Hempstead BL 1995 p75 and trk: a two-receptor
system. Trends Neurosci 18:321326[CrossRef][Medline]
-
Kaplan DR, Stephens RM 1994 Neurotrophin signal transduction
by the trk receptor. J Neurobiol 25:14041417[Medline]
-
Greene LA, Kaplan DR 1995 Early events in neurotrophin
signalling via trk and p75 receptors. Curr Top Neurobiol 5:579587[CrossRef]
-
Schlessinger J 2000 Cell signaling by receptor tyrosine
kinases. Cell 103:211225[Medline]
-
Yao R, Cooper GM 1995 Requirement for phosphatidylinositol-3
kinase in the prevention of apoptosis by nerve growth factor. Science 267:20032006[Medline]
-
Dobrowsky RT, Werher MM, Castellino AM, Chao MV, Hannun YA 1994 Activation of the sphingomyelin cycle through the low affinity
neurotrophin receptor. Science 265:15961599[Medline]
-
Brann AB, Scott R, Neuberger Y, Abulafia D, Boldin S,
Fainzilber M, Futerman AH 1999 Ceramide signalling downstream p75
neurotrophin receptor mediates the effects of nerve growth factor on
outgrowth of cultured hippocampal neurons. J Neurosci 19:81998206[Abstract/Free Full Text]
-
Carter BD, Lewin GR 1997 Neurotrophins live or let die: does
p75NTR decide? Neuron 18:187190[Medline]
-
Carter B, Kaltschmidt C, Kaltschmidt B, Offenhauser N,
Bohm-Matthaei R, Baeuerle PA, Barde YA 1996 Selective activation of
NF-
B by nerve growth factor through the neurotrophin receptor p75.
Science 272:542545[Abstract]
-
Foehr ED, Lin X, OMahony A, Geleziunas R, Bradshow RA,
Greene WC 2000 NF-
B signalling promotes both cell survival and
neurite process formation in nerve growth factor-stimulated PC12 cells.
J Neurosci 20:75567563[Abstract/Free Full Text]
-
Yoon SO, Casaccia-Bonnefil P, Carter B, Chao MV 1998 Competitive signalling between trkA and p75 nerve growth factor
receptors determines cell survival. J Neurosci 18:32733281[Abstract/Free Full Text]
-
Casaccia-Bonnefil P, Carter BD, Dobrowsky RT, Chao MV 1996 Death of oligodendrocytes mediated by the interaction of nerve growth
factor with its receptor p75. Nature 383:716719[CrossRef][Medline]
-
Bredesen DE, Rabizadeh S 1997 p75NTR and
apoptosis: trk-dependent and trk-independent effects. Trends Neurosci 20:287291[CrossRef][Medline]
-
Gentry JJ, Casaccia-Bonnefil P, Carter BD 2000 Nerve growth
factor activation of nuclear factor kB through its p75 receptor is an
antiapoptotic signal in RN22 Schwannoma cells. J Biol Chem 275:75587565[Abstract/Free Full Text]
-
Blochl A, Stirrenberg C 1996 Neurotrophins stimulate the
release of dopamine from rat mesencephalic neurons via trk and
p75(lntr) receptors. J Biol Chem 271:2110021107[Abstract/Free Full Text]
-
Stucki CL, Koltzenburg M 1997 The low-affinity neurotrophin
receptor p75 regulates the function but not the selective survival of
specific subpopulations of sensory neurons. J Neurosci 17:43984405[Abstract/Free Full Text]
-
Anton ES, Weskamp G, Reichardt LF, Mathew WD 1994 Nerve growth
factor and its low-affinity receptor promote Schwann cell migration.
Proc Natl Acad Sci USA 91:27952799[Abstract]
-
Bentley CA, Lee KF 2000 p75 Is important for axon growth and
Schwann cell migration during development. J Neurosci 20:77067715[Abstract/Free Full Text]
-
Dicou E, Lee J, Brachet P 1986 Synthesis of nerve growth
factor mRNA and precursor protein in the thyroid and parathyroid glands
of the rat. Proc Natl Acad Sci USA 83:70847088[Abstract]
-
Kanaka-Gantenbein C, Tazi A, Czernichow P, Scharfmann R 1995 In vivo presence of the high affinity nerve growth factor
receptor TrkA in the rat pancreas: differential localization during
pancreatic development. Endocrinology 136:761769[Abstract]
-
Kanaka-Gantenbein C, Dicou E, Czernichow P, Scharfmann R 1995 Presence of nerve growth factor and its receptors in an in
vitro model of islet cell development: implication in normal islet
morphogenesis. Endocrinology 136:31543162[Abstract]
-
Miralles F, Philippe P, Czernichow P, Scharfmann R 1998 Expression of nerve growth factor and its high-affinity receptor trkA
in the rat pancreas during embryonic and fetal life. J Endocrinol 156:431439[Abstract/Free Full Text]
-
Graham CW, Lynch JH, Djakiew D 1992 Distribution of nerve
growth factor-like protein and nerve growth factor receptor in human
benign prostatic hyperplasia and prostatic adenocarcinoma. J Urol 147:14441447[Medline]
-
Macgrogan D, Saint-Andrè JP, Dicou E 1992 Expression of
nerve growth factor and nerve growth factor receptor genes in human
tissues and prostatic adenocarcinoma cell lines. J Neurochem 59:13811391[Medline]
-
Paul AB, Grant ES, Habib FK 1996 The expression and
localization of ß-nerve growth factor (ß-NGF) in benign and
malignant human prostate tissue: relationship to neuroendocrine
differentiation. Br J Cancer 74:19901996[Medline]
-
Pflug BR, Onoda M, Lynch JH, Djakiew D 1992 Reduced expression
of the low affinity nerve growth factor receptor in benign and
malignant human prostate tissue and loss of expression in four human
metastatic prostate tumor cell lines. Cancer Res 52:54035406[Abstract]
-
Burnham P, Conner JM, Varon S 1995 Co-localization of NGF and
TSH-like immunoreactivity in cultures of adult rat anterior pituitary
cells. J Neurosci Res 41:7378[Medline]
-
Missale C, Boroni F, Sigala S, Buriani A, Fabris M, Leon A,
Dal Toso R, Spano PF 1996 Nerve growth factor in the anterior
pituitary: localization in mammotroph cells and co-secretion with
prolactin by a dopamine-regulated mechanism. Proc Natl Acad Sci USA 93:42404245[Abstract/Free Full Text]
-
Patterson JC, Childs GW 1994 Nerve growth factor in the
anterior pituitary: regulation of secretion. Endocrinology 135:16971704[Abstract]
-
Patterson JC, Childs GW 1994 Nerve growth factor and its
receptors in the anterior pituitary. Endocrinology 135:16891696[Abstract]
-
Missale C, Boroni F, Frassine M, Caruso A, Spano PF 1995 Nerve
growth factor promotes the differentiation of pituitary mammotroph
cells in vitro. Endocrinology 136:12051213[Abstract]
-
Paez-Pereda M, Missale C, Grubler Y, Artz E, Schaaf L, Stalla
GK 2000 Nerve growth factor and retinoic acid inhibit proliferation and
invasion in thyroid tumor cells. Mol Cell Endocrinol 167:99106[CrossRef][Medline]
-
Missale C, Codignola A, Sigala S, Finardi A, Paez-Pereda M,
Sher E, Spano PF 1998 Nerve growth factor abrogates tumorigenicity of
human small cell lung cancer cell lines. Proc Natl Acad Sci USA 95:53665371[Abstract/Free Full Text]
-
Polak M, Scharfmann R, Seilheimer B, Eisenbarth G, Dressler D,
Verma IM, Potter H 1993 Nerve growth factor induces neuron-like
differentiation of an insulin-secreting pancreatic ß cell line. Proc
Natl Acad Sci USA 90:57815785[Abstract]
-
Missale C, Boroni F, Losa M, Giovanelli M, Zanellato A, Dal
Toso R, Balsari A, Spano PF 1993 Nerve growth factor suppresses the
transforming phenotype of human prolactinomas. Proc Natl Acad Sci USA 90:79617965[Abstract/Free Full Text]
-
De Camilli P, Macconi D, Spada A 1979 Dopamine inhibits
adenylate cyclase in human prolactin-secreting adenomas. Nature 278:252254[Medline]
-
Missale C, Nash SR, Robinson SW, Jaber M, Caron MG 1998 Dopamine receptors: from structure to function. Physiol Rev 78:189225[Abstract/Free Full Text]
-
Pellegrini I, Rosolonjanahari R, Gunz G, Bertrand P, Delivet
S, Jedynak CP, Kordon C, Peillon F, Jacquet P, Enjalbert A 1989 Resistance to bromocriptine in prolactinomas. J Clin Endocrinol
Metab 69:500509[Abstract]
-
Missale C, Losa M, Sigala S, Balsari A, Giovanelli M, Spano PF 1996 Nerve growth factor controls proliferation and progression of
human prolactinoma cell lines through an autocrine mechanism. Mol
Endocrinol 10:272285[Abstract]
-
Ross AH, Grob P, Bothwell M, Elder DE, Ernst CS, Marano N,
Ghrist BFD, Slemp CC, Herlyn M, Atkinson B, Koprowski H 1984 Characterization of nerve growth factor receptor in neural crest tumors
using monoclonal antibodies. Proc Natl Acad Sci USA 81:66816685[Abstract]
-
Huber LJ, Chao MV 1995 Mesenchymal and neuronal cell
expression of the p75 neurotrophin receptor gene occur by different
mechanisms. Dev Biol 167:227238[CrossRef][Medline]
-
Koizumi S, Contreras ML, Matsuda Y, Hama T, Lazarovich P,
Guroff G 1988 K-252a: a specific inhibitor of the action of nerve
growth factor on PC12 cells. J Neurosci 8:715721[Abstract]
-
Berg MM, Sternberg DW, Parada LF, Chao MV 1992 K-252a inhibits
nerve growth factor-induced trk proto-oncogene tyrosine phosphorylation
and kinase activity. J Biol Chem 267:1316[Abstract/Free Full Text]
-
Martin-Zanca R, Oskam R, Mitra G, Copeland T, Barbacid M 1989 Molecular and biochemical characterization of the human trk
proto-oncogene. Mol Cell Biol 9:2433[Medline]
-
Maliartchouk S, Saragovi HU 1997 Optimal nerve growth factor
trophic signals mediated by synergy of trkA and p75 receptor-specific
ligands. J Neurosci 17:60316037[Abstract/Free Full Text]
-
Dikic I, Batzer AG, Blaikie P, Obermeier A, Ullrich A,
Schlessinger J, Margolis B 1995 Shc binding to nerve growth factor
receptor is mediated by the phosphotyrosine interaction domain.
J Biol Chem 270:1512515129[Abstract/Free Full Text]
-
Knusel B, Hefti F 1992 K-252 compounds: modulators of
neurotrophin signal transduction. J Neurochem 59:19871996[Medline]
-
Gandelman KY, Harmon S, Todd RD, OMalley KL 1991 Analysis of
the structure and expression of the human dopamine
D2A receptor gene. J Neurochem 56:10241029[Medline]
-
Baeuerle PA, Baltimore D 1996 NF-
B: ten years after. Cell 87:1320[Medline]
-
ONeill LAJ, Kaltschmidt C 1997 NF-
B: a crucial
transcription factor for glial and neuronal cell function. Trends
Neurosci 20:252258[CrossRef][Medline]
-
Sen R, Baltimore D 1986 Multiple factors interact with the
immunoglobulin enhancer sequences. Cell 46:706716
-
Lin YZ, Yao SY, Veach RA, Torgerson TR, Hawiger J 1995 Inhibition of nuclear translocation of NF-
B by a synthetic peptide
containing a cell membrane-permeable motif and nuclear localization
sequence. J Biol Chem 270:1425514258[Abstract/Free Full Text]
-
Maggirvar SB, Sarmiere PD, Dewhurst, Freeman RS 1998 Nerve
growth factor-dependent activation of NF-
B contributes to survival
of sympathetic neurons. J Neurosci 18:1035610365[Abstract/Free Full Text]
-
Sortino MA, Condorelli F, Vancheri C, Chiarenza A, Bernardini
R, Consoli U, Canonico PL 2000 Mitogenic effect of nerve growth factor
(NGF) in LNCaP prostate adenocarcinoma cells: role of the high- and
low-affinity NGF receptors. Mol Endocrinol 14:124136[Abstract/Free Full Text]
-
Kukstas LA, Domec C, Bascles L, Bonnet J, Venier D, Israel JM,
Vincent JD 1991 Different expression of the two dopaminergic
D2 receptors, D2415 and
D2444, in two types of lactotroph each
characterized by their response to dopamine and modification of
expression by sex steroids. Endocrinology 129:11011103[Abstract]
-
Guivarch D, Vincent JD, Vernier P 1998 Alternative splicing
of the D2 dopamine receptor messenger ribonucleic acid is modulated by
activated sex steroid receptors in the MMQ prolactin cell line.
Endocrinology 139:42134221[Abstract/Free Full Text]
-
Grilli MG, Ribola M, Alberici A, Valerio A, Memo M, Spano PF 1995 Identification and characterization of a
B/Rel binding site in
the regulatory region of the amyloid precursor protein gene. J
Biol Chem 270:2677426777[Abstract/Free Full Text]
-
Liou HC, Baltimore D 1993 Regulation of the NF-
B/Rel
transcription factor and I-
B inhibitory system. Curr Opin Cell Biol 5:477487[Medline]
-
Minowa T, Minowa MT, Mouradian MM 1993 Negative modulator of
the rat D2 dopamine receptor gene. J Biol
Chem 269:1165611662[Abstract/Free Full Text]
-
Valdenaire O, Vernier P, Maus M, Dumas Milne Edwards JP,
Mallet J 1994 Transcription of the rat
dopamine-D2-receptor gene from two promoters. Eur
J Biochem 220:577584[Abstract]
-
Wang J, Miller JC, Friedhoff AJ 1997 Differential regulation
of D2 receptor gene expression by transcription
factor AP-1 in cultured cells. J Neurosci Res 50:2331[CrossRef][Medline]
-
Yajima S, Lee SH, Minowa T, Mouradin MM 1998 Sp family
transcription factors regulate expression of rat
D2 dopamine receptor gene. DNA Cell Biol 17:471479[Medline]
-
Krezel W, Ghyselink N, Samad TA, Dupe V, Kastner P, Borrelli
E, Chambon P Impaired locomotion and dopamine signalling in retinoid
receptor mutant mice. Science 279:863867
-
Samad TA, Krezel W, Chambon P, Borrelli E 1997 Regulation of
dopaminergic pathways by retinoids: activation of the
D2 gene promoter by members of the retinoic acid
receptor-retinoid X receptor family. Proc Natl Acad Sci USA 94:1434914354[Abstract/Free Full Text]
-
Baik JH, Picetti R, Saiardi A, Thiriet G, Dietrich A, Depaulis
A, Le Meur M, Borrelli E 1995 Parkinsoninan-like locomotor impairment
in mice lacking dopamine D2 receptors. Nature 377:424428[CrossRef][Medline]
-
Saiardi A, Bozzi Y, Baik JH, Borrelli E 1997 Antiproliferative
role of dopamine: loss of D2 receptors causes
hormonal dysfunction and pituitary hyperplasia. Neuron 19:115126[Medline]
-
Asa SL, Kelly MA, Grandy DR, Low MJ 1999 Pituitary lactotroph
adenomas develop after prolonged lactotroph hyperplasia in dopamine
D2 receptor-deficient mice. Endocrinology 140:53485355[Abstract/Free Full Text]
-
Arinami T, Gao M, Hamaguchi H, Torn M 1997 A functional
polymorphism in the promoter region of the dopamine D2 receptor gene is
associated with schizophrenia. Hum Mol Genet 6:577582[Abstract/Free Full Text]
-
Crenon I, Béraud C, Simard P, Montagne J, Veschambre P,
Jalinot P 1993 The transcriptionally active factors mediating the
effect of the HTLV-I Tax transactivator on the IL-2R
B enhancer
include the product of the c-rel proto-oncogene. Oncogene 8:867875[Medline]